New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
08:14 EDTGHDXGenomic Health's Oncotype DX for prostate cancer shows positive results
Genomic Health announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research demonstrating that the Oncotype DX Genomic Prostate Score predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a predictor of biochemical recurrence, a rise in prostate-specific antigen following surgery, which is a measure of longer-term outcomes for aggressive disease. Additional endpoints of this prostate cancer study include the development of metastatic disease and outcomes in African-American patients.
News For GHDX From The Last 14 Days
Check below for free stories on GHDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
08:05 EDTGHDXGenomic Health to present positive results from nine studies of Oncotype DX
Genomic Health announced that results from nine studies of Oncotype DX in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology, or ESMO, 2014 Congress in Madrid, September 26 30. Included in the program is the first presentation of strongly positive results from an additional large independent clinical validation study of the Oncotype DX prostate cancer test, conducted in collaboration with the Center for Prostate Disease Research, Rockville. This new study demonstrates the test's ability to predict a rise in prostate-specific antigen, or PSA, following surgery and reconfirms Oncotype DX as a predictor of adverse pathology from the biopsy, as previously demonstrated in a published validation study performed by the University of California, San Francisco.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use